Drug Development

Zervimesine (CT1812) is an experimental oral, small-molecule drug candidate in development for Alzheimer's disease and dementia with Lewy bodies (DLB). Zervimesine is designed to protect neurons by preventing the binding of oligomers of pathogenic proteins including β-amyloid and ɑ-synuclein. T...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia 2025-12, Vol.21 Suppl 5, p.e106890
Main Authors: Galvin, James E, Hamby, Mary E, Iaci, Jennifer, Grundman, Michael, Caggiano, Anthony O
Format: Article
Language:English
Subjects:
Activities of Daily Living
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy
Double-Blind Method
Drug Development
Female
Humans
Lewy Body Disease - drug therapy
Male
Middle Aged
Neuropsychological Tests
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!